
-
Xeris Pharmaceuticals NASDAQ:XERS Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Location: | Website: www.xerispharma.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
760.6M
Cash
69.4M
Avg Qtr Burn
-7.871M
Short % of Float
7.40%
Insider Ownership
3.93%
Institutional Own.
44.93%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Gvoke® Details Diabetes | Approved Quarterly sales | |
Recorlev® (levoketoconazole) Details Rare diseases, Cushing’s syndrome | Approved Quarterly sales | |
Keveyis® (dichlorphenamide) Details Rare diseases | Approved Quarterly sales | |
XeriSol® (Levothyroxine) (XP-8121) Details Adult hypoparathyroidism | Phase 2 Update | |
Failed Discontinued | ||
Gvoke RTU Micro™ Details Hypoglycemia, Type 1 diabetes, Type 2 diabetes | Failed Discontinued | |
Pramlintide-Insulin Details Type 1 diabetes, Diabetes, Type 2 diabetes | Failed Discontinued |